Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Inclusion Criteria:

   - Subjects with suspected brain tumors undergoing surgical removal as their standard of
   care will be eligible; these may include subjects' status post chemotherapy and/or
   radiation or subjects who have undergone diagnostic biopsy for their original
   diagnosis and are assessed to be candidates for resection

   - Subjects must be eligible for resection as determined by the operating surgeon

   - Platelet count ≥ 75,000/mm^3

Exclusion Criteria:

   - Received an investigational drug within 30 days prior to first dose of
   panitumumab-IRDye800

   - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
   heart failure (CHF); significant liver disease; or unstable angina within 6 months
   prior to enrollment

   - History of infusion reactions to monoclonal antibody therapies

   - Pregnant or breastfeeding

   - Evidence of corrected QT (QTc) prolongation on pre-treatment electrocardiography (ECG)
   (greater than 440ms in males or greater than 460ms in females)

   - Thyroid-stimulating hormone (TSH) ≥ 13 micro international units/mL

   - Magnesium, potassium and calcium < the lower limit of normal per institution normal
   lab values

   - Other lab values that in the opinion of the primary surgeon would prevent surgical
   resection

   - Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide,
   amiodarone, sotalol) antiarrhythmic agents

   - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis

   - Subjects not deemed to be appropriate candidates for optimal resection of tumor based
   on location, involvement of eloquent brain, satellite lesions, or other factors not
   specifically listed here